Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
AVANT BIO is a Delaware limited liability company specializing in the life sciences sector. The firm focuses on companies that merge advanced technologies with novel therapeutics to tackle unmet therapeutic development needs. They operate primarily in North America and Europe.
AVANT BIO invests in therapeutic enabling technologies, biomanufacturing tools, and AI applications within healthtech and techbio. Their thematic focus includes equitable access to therapies, improving drug discovery speed and quality, and enhancing clinical trial diversity.
AVANT BIO's portfolio features several notable companies: Better Medicine, Faster with AI and Lab Automation (Toronto, Ontario, Canada), Protein Profiling, Unleashed (Montréal, Québec, Canada), Image Management Simplified (Montville, NJ, USA), and Innovating Cell Culture (Aachen, Germany and Paris, France), all active investments since 2025 or 2026.
Submit through their form at avant.bio.
AVANT BIO typically participates in leading investment rounds, especially in early-stage companies that align with their focus areas.
The firm is open to follow-on investments, particularly for companies that demonstrate significant progress and alignment with their thematic focus.
Specific details about the size of AVANT BIO's current fund are not publicly available.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.